DRDO conducts flight demonstration of Controlled Aerial Delivery System | Video

The CADS-500 system was para-dropped from an AN32 aircraft and then steered to the predesignated landing point in autonomous mode.

The CADS-500 system was para-dropped from an altitude of 5,000 metres. (Photo: Twitter/@DRDO_India)

The Defence Research and Development Organisation’s R&D lab conducted a flight demonstration of Controlled Aerial Delivery System of 500 kg capacity (CADS-500) on Saturday, the Ministry of Defence said.The system, developed by Aerial Delivery Research and Development Establishment (ADRDE) in Agra, was para-dropped from an AN32 aircraft and then steered to the predesignated landing point in autonomous mode. Eleven paratroopers of the Indian Army and Indian Air Force chased the CADS-500 in the air and landed simultaneously at the drop zone in Malpura from an altitude of 5,000 metres.

Controlled Aerial Delivery System of 500 kg (CADS-500) lands precisely during demonstration trials by #ADRDE, DRDO. #AmritMahotsav #AtmaNirbharBharat https://t.co/Se51Kcp4ug pic.twitter.com/Vr8xBDkRQ5

— DRDO (@DRDO_India) December 19, 2021

The CADS-500 is used for precise delivery of payload up to 500 kgs at a predetermined location by making use of manoeuvrable capabilities of the Ram Air Parachute (RAP).It uses Global Positioning System for the coordinates, altitude and heading sensors for the heading information during its flight.The CADS, with its onboard electronics unit, autonomously steers its flight path using waypoint navigation towards target location by operating controls.The flight demonstration was part of a series of activities to celebrate ‘Azadi Ka Amrit Mahotsav’, commemorating 75 years of India’s independence.READ | Nuclear-capable Agni-P missile successfully flight testedDRDO, IAF successfully flight-test indigenous Stand-Off Anti-Tank missile | WATCH

Click here for IndiaToday.in’s complete coverage of the coronavirus pandemic.

Note: This article have been indexed to our site. We do not claim legitimacy, ownership or copyright of any of the content above. To see the article at original source Click Here

Related Posts
KFF Health News' 'What the Health?': A Year Without Roe thumbnail

KFF Health News’ ‘What the Health?’: A Year Without Roe

KFF Health News’ ‘What the Health?’ Episode Title: A Year Without Roe Episode Number: 304 Published: June 29, 2023 [Editor’s note: This transcript, generated using transcription software, has been edited for style and clarity.] Julie Rovner: Hello and welcome back to “What the Health?” I’m Julie Rovner, chief Washington correspondent at KFF Health News. We’re
Read More
First AKT Inhibitor Approved for Advanced Breast Cancer thumbnail

First AKT Inhibitor Approved for Advanced Breast Cancer

Oncology/Hematology > Breast Cancer — Capivasertib plus fulvestrant doubled progression-free survival versus fulvestrant-placebo by Charles Bankhead, Senior Editor, MedPage Today November 17, 2023 The FDA approved the first-in-class AKT inhibitor capivasertib (Truqap), in combination with fulvestrant, for locally advanced/metastatic hormone receptor (HR)-positive/HER2-negative breast cancer and at least one specific genetic alteration. The approval stipulates use
Read More
Is hydroxychloroquine a treatment for COVID-19? thumbnail

Is hydroxychloroquine a treatment for COVID-19?

Hydroxychloroquine is not recommended as a treatment for coronavirus disease 2019 (COVID-19). Also, hydroxychloroquine doesn't prevent infection with the virus that causes COVID-19. In March 2020, the U.S. Food and Drug Administration, also called the FDA, allowed emergency use of hydroxychloroquine and chloroquine to treat COVID-19. The FDA based this authorization on data collected from
Read More
Index Of News
Total
0
Share